Immuno-oncologyHCW Biologics seeks pre-IND meeting with FDA for HCW-11-018bHCW Biologics Inc. has requested a type B (pre-IND) meeting with the FDA to discuss the development and regulatory strategy for its investigational tetravalent T-cell engager (TCE), HCW-11-018b, for solid tumors.